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effusion is diagnostic of primary effusion lymphoma (formerly
known as body cavity lymphoma), a type of large B-cell lymphoma
underwent 6 cycles of chemotherapy, and at the time of writing, is
in complete remission with an undetectable viral load, although he
has still not achieved immune reconstitution.with plasmablastic differentiation associated with human herpes
virus 8 (HHV-8) and typically affecting immunosuppressed
patients. Serological analysis was then requested, which was
positive for human immunodeficiency virus (HIV-1) (chemilumi-
nescence with Western blot confirmation) and HHV-8 infection
(immunoglobulin G titer, 1/160, and positive polymerase chain
reaction testing). In the assessment of disease extension, there was
no evidence of lymphadenopathies or hepatosplenomegaly, and
bone marrow biopsy yielded normal results. Pericardial fluid
culture was negative.
Based on these findings, a diagnosis of primary effusion
lymphoma associated with HIV/AIDS (Category C) was estab-
lished. CD4 cell count at the time of diagnosis was 104 cells/mL and
viral load was 103 000 copies/mL. Antiretroviral treatment (ART)
was started with emtricitabine, tenofovir, and raltegravir, and
polychemotherapy was subsequently added (DA-EPOCH regi-
men).
In 2015 in Spain, 3428 new cases of HIV infection were notified,
representing a rate of 7.39 new HIV diagnoses per 100 000 popula-
tion per year. Almost half of these cases were late diagnoses, when
1CD4 counts were < 350 cells/mL. Since the introduction of ART, the
prognosis of HIV patients has radically changed, with a consider-
able increase in survival. In addition, this treatment has led to a
decrease in associated pericardial, myocardial, and valvular heart
diseases. In the pre-ART era, pericardial disease was the most
common cardiac manifestation in HIV patients,2,3 and the
estimated prevalence of pericardial effusion was 11%.4 Although
these effusions are mainly idiopathic, some may be related to
opportunistic infections or various types of cancer, such as
lymphoma or Kaposi sarcoma. For this reason, HIV infection
should be included in the differential diagnosis of pericardial
effusion of uncertain etiology.5
Primary effusion lymphoma is an uncommon (4% of HIV-
associated lymphomas) and very aggressive form of non-Hodgkin,
diffuse, large B-cell lymphoma that develops exclusively in severely
immunosuppressed individuals, generally patients with HIV and
very low CD4 lymphocyte counts. Affected patients characteristi-
cally have B symptoms (fever, weight loss, night sweats) associated
with lymphomatous pleural, pericardial, or peritoneal effusion,
without tumor masses, lymphadenopathies, organomegaly, or bone
marrow infiltration. The causal agent is HHV-8, the same virus that
causes Kaposi sarcoma. This type of lymphoma has a very poor
prognosis, with an overall survival of < 6 months. However,
prognosis can be improved by the use of ART.6 The patient reported
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To the Editor,
This report describes a unique case of genetically confirmed
overlap of type-1 facioscapulohumeral muscular dystrophy
(FSHD1) and obstructive sarcomeric hypertrophic cardiomyopathy
(sHCM).
We present the case of a 37-year-old woman, diagnosed with
FSHD1 and sHCM with substantial left ventricular (LV) hypertro-Because of the aggressiveness and unfavorable prognosis of this
type of lymphoma, it could be advisable to include it in the initial
clinical suspicion whenever HIV-infected patients develop peri-
cardial effusion of uncertain etiology. Flow cytometry is an
important diagnostic technique for these cases, as it allows fast
identification of lymphomatous cells suspended in the infiltrated
fluid. An early diagnosis would enable initiation of targeted
treatment that could improve survival and quality of life in these
patients
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C 2017 Sociedad Española de Cardiologı́a. Published by Elsevier España, S.L.U. All
rights reserved.
phy and severe symptomatic LV outflow tract obstruction.
Molecular analysis confirmed the presence of contraction of the
specific 18Kb fragment in the D4Z4 locus of chromosome 4q and
the haplotype 4qA, confirming the diagnosis of FSHD1, and the
presence of the previously described c.1800.delA (p.Lys600Asnfs*)
pathogenic mutation in the MYBPC3 gene, confirming the diagnosis
of sHCM.1 The patient’s father had the FSHD1 phenotype, although
molecular analysis was not available. The patient’s mother had the
same pathogenic mutation on the MYBPC3 gene, although she had
only a mild phenotype.
The first symptoms of FSHD1 arose at age 5 years with
decreased strength of facial muscles and inability to smile or
whistle. In the third decade of life, an asymmetric reduction in
upper limb strength developed. Neurological evaluation was
remarkable for typical FSHD1 phenotype with bilateral peripheral
facial paresis, atrophy of the pectoral muscles and winged
scapulae. The electromyogram showed myopathic changes in
the orbicularis and trapezius muscles. Creatinine kinase levels
were normal.
Also in the third decade of life, the patient developed effort
dyspnea (New York Heart Association III functional class) and
presyncope. N-terminal pro-B-type natriuretic peptide levels were
increased (400 pg/mL). Electrocardiography revealed LV hypertro-
phy (voltage criteria) and T-wave inversion in the inferior leads.
Serial echocardiograms showed septal asymmetric hypertrophy
(interventricular septum = 25 mm, pulse wave = 13 mm), severe
LV outflow tract obstruction (rest peak gradient = 40 mmHg;
exercise stress peak gradient = 100 mmHg), anterior systolic
motion of the anterior mitral leaflet associated with moderate
mitral regurgitation, and grade II diastolic dysfunction. Episodes of
nonsustained monomorphic ventricular tachycardia were found
on 24-hour Holter monitoring. A single chamber implantable
cardioverter-defibrillator was implanted.
Titration of beta-blocker therapy was not tolerated (hypoten-
sion) and alcohol septal ablation was considered. Coronary
angiography was performed, showing the presence of 2 septal
arteries that were candidates for alcohol septal ablation. Although
the first septal artery irrigated the region of interest, the contrast
opacification was suboptimal. The second septal artery irrigated the
right portion of the septum, inferior wall, and posteromedial
papillary muscle. We considered that the risk-benefit ratio was
unfavorable and the patient underwent surgical myectomy. The
postoperative period was complicated by complete atrioventricular
block, and the monochamber implantable cardioverter-defibrillator
was upgraded to a dual-chamber implantable cardioverter-
defibrillator.
At 2 years of follow-up, the patient is only mildly symptomatic
(New York Heart Association functional class I-II), with no
Scientific letters / Rev Esp Cardiol. 2018;71(9):755–769766dysrhythmic events. An echocardiogram showed a decrease in
the asymmetric septal hypertrophy (interventricular sep-
tum = 14 mm, pulse wave = 13 mm) and a resting peak gradient
of 40 mmHg, but with no further increase on exercise stress
testing.
Both FSHD1 due to contraction of the D4Z4 locus in the
subtelomeric 4q35 region and sHCM due to MYBPC3 pathogenic
mutation c.1800.delA (p.Lys600Asnfs*) were identified in the
patient described. To the best of our knowledge, there are no
published cases describing the co-occurrence of FSHD1 and sHCM.
Epidemiologic studies suggest that the frequency of FSHD is about
1:20 000, while the frequency of sHCM is estimated to be 1:500.2
Thus, the chance of being affected by both disorders is about
1:10 000 000.
In contrast to other muscular dystrophies such as Duchenne’s
where the development of dilated cardiomyopathy and heart
failure are common, cardiac involvement in FSHD1 is rare and is
characterized by conduction abnormalities and supraventricular
dysrhythmias. Three cases in the medical literature describe
cardiomyopathy associated with FSHD1.3–5 Finsterer et al.3
describe a 50-year-old FSHD1 and hypertensive patient (blood
pressure 150/90 mmHg) with electrocardiographic abnormalities
and left ventricular hypertrophy. Emmrich et al.4 report a 71-year-
old woman with FSHD1 and progressive heart failure whose
autopsy revealed normal muscle mass volume and histological
changes seen in primary cardiomyopathies. In both cases, no
molecular testing was performed and conflicting clinical data exist
about the presence of cardiomyopathy. The last case, by Tsujiet al.,5 concerns a 38-year-old FSHD1 patient with associated
retinal vasculopathy and neurosensorial hearing impairment,
whose echocardiogram showed mild dilatation of the LV associat-
ed with poor contractility; cardiac histopathology revealed marked
disarray and mild fibrosis, suggesting a dilated phase of sHCM
rather than dilated cardiomyopathy. Also, no molecular testing
was reported.
In addition to the pathogenic mutation in the MYBPC3 gene, our
patient had the following variants of unknown significance:
p.Cys5939Tyr and p.Lys14140Val in the TTN gene, and p.Tyr904Cys
in the Ryr2 gene. Her mother also had the same variants of
unknown significance in the TTN gene. Because of the genetic
complexity of sHCM, clinical interpretation of a large number of
rare variants of unknown significance with uncertain effects on
gene function identified with current sequencing technology
testing is a real challenge. Ideally, novel variants of unknown
significance should undergo functional studies, but these are time-
consuming, costly, and often impractical in the clinical setting.
Similarly, cosegregation analysis within families may be helpful,
but is uninformative in small pedigrees and is often difficult to
orchestrate.6
This case report describes a unique patient with genetically
confirmed overlapping diagnoses of FSHD1 and severe obstructive
sHCM. Proper clinical and genetic evaluation of these overlapping
patients is critical for their management. This case also highlights
the importance of cardiological evaluation in patients with
muscular dystrophies.
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